Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Have you heard from her?

We’re referring to the renowned women leaders from across the healthcare landscape who were our guests on Season 1 of Medscape Education’s Hear From Her podcast series. The conversations touched...

Medscape Education

- PMLiVE

Ipsen’s Onivyde regimen granted FDA approval to treat pancreatic cancer

Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year

Biogen Idec building

Biogen receives EC approval for Skyclarys in Friedreich’s ataxia patients

The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals

- PMLiVE

MHRA launches second phase of genetic biobank for stroke prevention medicines

The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban

- PMLiVE

New type of inhibitor drug could prevent microvascular diabetic complications

The drug could prevent conditions including diabetic eye and kidney disease in diabetes

Diversity icons in Cuttsy+Cuttsy branded shapes

Clinical trial considerations: Why diversity matters…

Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here's why diversity matters...

Cuttsy + Cuttsy

Rare Disease Diagnostic Odyssey

Medscape Education

- PMLiVE

Gilead expands liver disease pipeline with $4.3bn CymaBay acquisition

The deal gives the company access to a candidate being evaluated in primary biliary cholangitis

EU flag

EC approves Vertex/CRISPR’s Casgevy gene therapy for inherited blood disorders

There are now more than 8,000 patients who are potentially eligible for treatment with Casgevy

Biomarin

BioMarin shares long-term results for haemophilia A gene therapy Roctavian

Approximately one in 10,000 people are affected by the genetic blood clotting disorder

- PMLiVE

Sanofi presents positive results for Pompe disease enzyme replacement therapy

The rare genetic disorder is estimated to affect around one in every 40,000 people in the UK

- PMLiVE

ICR researchers reveal how advanced breast cancers become resistant to hormone therapy

F404 mutations combined with pre-existing mutations caused resistance to fulvestrant

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links